C-to-G Base Editor
C-to-G transversion base editor expanding beyond transition mutations. Enables targeted C-to-G conversion addressing 11-40% of disease SNPs.
| Origin | Engineered APOBEC1 variants or R33A mutant with uracil DNA glycosylase |
|---|---|
| Conversion Type | C-to-G |
| Editor Type | C-to-G Base Editor |
| Editing Window | Positions 4-8 |
Characteristics
Achieves 5-30% C-to-G editing efficiency depending on sequence context and architecture. Requires cellular base excision repair pathway for transversion outcome. Multiple architectures available: CGBE1 with eUNG, or rXRCC1/Polβ fusion variants.
Applications
Enables C-to-G transversions correcting disease mutations inaccessible to transition base editors. Particularly effective in AT-rich sequence contexts. Expands therapeutic scope when combined with CBE/ABE to address 40% of ClinVar disease SNVs.
Limitations
Lower efficiency (5-30%) than transition base editors with higher sequence dependence. Byproduct indels more common than CBE/ABE systems. Product purity variable; C-to-A and C-to-T byproducts require careful optimization for specific targets.
Architecture
Cytosine base editor fused with uracil DNA glycosylase (UNG) instead of UGI. UNG excises deaminated uracil, creating abasic site that is repaired to G opposite template C.
Sequence1,000 bp
Sign in to view the full sequence.
Sign inReferences
- 1.Chen et al. (2021). Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins. Nat Commun — Chen 2021 CGBE
- 2.Koblan et al. (2021). Efficient C•G-to-G•C base editors developed using CRISPRi screens, target-library analysis, and machine learning. Nat Biotechnol — Koblan 2021 CGBE SuiteCorrected
- 3.Kurt et al. (2020). CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. Nat Biotechnol — Kurt 2020 CGBE1
